Bausch+Lomb Results Presentation Deck
Completed Xiidra Acquisition, Transformed Pharmaceuticals Business
Specifically approved to treat
signs and symptoms of DED,
focusing on inflammation
associated with dry eye
xiidra
(lifitegrast
ophthalmic solution) 5%
WELCOME TEAM
BAUSCH + LOMB
Xiidra
(lifitegrast
ophthalmic solution) 5%
FELCOME
TEAM
xidra
u
xiidra
Efterpast
tanic solution
Completed acquisition of Xiidra in
September 2023, focused on
transition in Q4 2023 and relaunch
Differentiated clinical profile - Signs and
symptoms of DED focusing on inflammation
Well established - Xiidra is a leading DED
branded Rx product in the market
Competitive formulary coverage and proven
market access track record
Strong intellectual property portfolio, generics
settlements reached for Q2 2032 entry
15View entire presentation